PSTI Stock - Pluristem Therapeutics Inc.
Unlock GoAI Insights for PSTI
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2025 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Revenue | $1.34M | N/A | $23,000 | $54,000 | $50,000 |
| Gross Profit | $654,000 | N/A | $23,000 | $52,000 | $48,000 |
| Gross Margin | 49.0% | N/A | 100.0% | 96.3% | 96.0% |
| Operating Income | $-23,329,000 | $-50,623,000 | $-29,476,000 | $-35,532,000 | $-33,731,000 |
| Net Income | $-23,250,000 | $-49,865,000 | $-29,152,000 | $-35,307,000 | $-26,126,000 |
| Net Margin | -1740.3% | N/A | -126747.8% | -65383.3% | -52252.0% |
| EPS | $-3.56 | $-1.77 | $-1.60 | $-2.86 | $-2.47 |
Pluristem Therapeutics Inc. operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the recovery after surgery for hip fracture; in Phase II clinical trail for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18, which has completed Phase I clinical trial incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of acute radiation syndrome. The company has a license agreement for conducting clinical trials of PLX-PAD product in South Korea. It also has a collaborative project nTRACK, that examines gold nano particles labeling of stem cells; and has collaboration agreement with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions. Pluristem Therapeutics Inc. was incorporated in 2001 and is based in Haifa, Israel.
Visit WebsiteEarnings History & Surprises
PSTIEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2022 | Sep 12, 2022 | $-0.02 | $-0.49 | -2359.4% | ✗ MISS |
Q2 2022 | May 9, 2022 | $-0.36 | $-0.31 | +13.9% | ✓ BEAT |
Q1 2022 | Mar 31, 2022 | — | $-0.31 | — | — |
Q1 2022 | Feb 7, 2022 | $-0.38 | $-0.34 | +10.5% | ✓ BEAT |
Q4 2021 | Dec 31, 2021 | — | $-0.34 | — | — |
Q4 2021 | Nov 8, 2021 | $-0.41 | $-0.36 | +12.2% | ✓ BEAT |
Q3 2021 | Sep 30, 2021 | — | $-0.36 | — | — |
Q3 2021 | Sep 13, 2021 | $-0.40 | $-0.46 | -15.0% | ✗ MISS |
Q2 2021 | May 6, 2021 | $-0.33 | $-0.48 | -45.5% | ✗ MISS |
Q1 2021 | Feb 8, 2021 | $-0.26 | $-0.49 | -88.5% | ✗ MISS |
Q4 2020 | Nov 5, 2020 | $-0.10 | $-0.33 | -230.0% | ✗ MISS |
Q3 2020 | Sep 10, 2020 | $-0.36 | $-0.32 | +11.1% | ✓ BEAT |
Q2 2020 | May 11, 2020 | $-0.36 | $-0.42 | -16.7% | ✗ MISS |
Q1 2020 | Feb 6, 2020 | $-0.52 | $-0.40 | +23.1% | ✓ BEAT |
Q4 2019 | Nov 7, 2019 | $-0.66 | $-0.46 | +30.3% | ✓ BEAT |
Q3 2019 | Sep 12, 2019 | $-0.63 | $-0.63 | 0.0% | = MET |
Q2 2019 | May 6, 2019 | $-0.75 | $-0.90 | -20.0% | ✗ MISS |
Q1 2019 | Feb 6, 2019 | $-0.85 | $-0.70 | +17.6% | ✓ BEAT |
Q4 2018 | Nov 7, 2018 | $-0.90 | $-0.80 | +11.1% | ✓ BEAT |
Q3 2018 | Sep 12, 2018 | $-0.70 | $-0.90 | -28.6% | ✗ MISS |
Latest News
Frequently Asked Questions about PSTI
What is PSTI's current stock price?
What is the analyst price target for PSTI?
What sector is Pluristem Therapeutics Inc. in?
What is PSTI's market cap?
Does PSTI pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to PSTI for comparison